Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2007 Nov 15.

Published in final edited form as: J Nucl Med. 2002 May;43(5):678–692.

Time–activity curves obtained with (+)-¹¹C-McN5652 (left) and ¹¹C-DASB (right) in various ROIs. Shown are results under baseline conditions and after MDMA treatment and paroxetine pretreatment. Data are expressed in units of nCi/mL/mCi (37 Bq/mL/37 MBq) ID. Measured data are displayed with circles; curves fitted on basis of 3-parameter, 1-tissue compartment model are displayed with lines. Both radioligands show decreased binding in MDMA-treated animal compared with control animal. With both radioligands, paroxetine increased amount of radioactivity reaching brain, measured as time integral of unmetabolized radioligand concentration in arterial plasma. (Continued on page 684.)

Time–activity curves obtained with (+)-¹¹C-McN5652 (left) and ¹¹C-DASB (right) in various ROIs. Shown are results under baseline conditions and after MDMA treatment and paroxetine pretreatment. Data are expressed in units of nCi/mL/mCi (37 Bq/mL/37 MBq) ID. Measured data are displayed with circles; curves fitted on basis of 3-parameter, 1-tissue compartment model are displayed with lines. Both radioligands show decreased binding in MDMA-treated animal compared with control animal. With both radioligands, paroxetine increased amount of radioactivity reaching brain, measured as time integral of unmetabolized radioligand concentration in arterial plasma. (Continued on page 684.)

HHS Vulnerability Disclosure